Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H32N2 |
| Molecular Weight | 240.428 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
C[N+]2(CCCCC[N+]1(C)CCCC1)CCCC2
InChI
InChIKey=XSBSKEQEUFOSDD-UHFFFAOYSA-N
InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2
| Molecular Formula | C15H32N2 |
| Molecular Weight | 240.428 |
| Charge | 2 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
Other AEs: Dizziness, Constipation... Other AEs: Dizziness Sources: Constipation Vomiting Paralytic ileus (grade 5) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Constipation | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
| Dizziness | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
| Vomiting | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
| Paralytic ileus | grade 5 | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Receptor protection studies to characterize neuronal nicotinic receptors: tubocurarine prevents alkylation of adrenal nicotinic receptors. | 2001 Feb 9 |
|
| Upregulation of immunoreactive angiotensin II release and angiotensinogen mRNA expression by high-frequency preganglionic stimulation at the canine cardiac sympathetic ganglia. | 2001 Jan 19 |
|
| Central orexin-A augments sympathoadrenal outflow in conscious rabbits. | 2001 Jun |
|
| Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. | 2001 Jun |
|
| Blood pressure, heart rate, and behavioral responses to psychological "novelty" stress in freely moving rats. | 2001 May |
|
| Sympathetic blockade significantly improves cardiovascular alterations immediately after spinal cord injury in rats. | 2002 Feb 15 |
|
| The altered balance between sympathetic nervous system and nitric oxide in salt hypertensive Dahl rats: ontogenetic and F2 hybrid studies. | 2002 May |
|
| In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission. | 2002 May 31 |
|
| Human coagulation factor XII-related "new pressor protein": role of PACAP in its cardiovascular and sympathoadrenal effects. | 2002 Oct |
|
| Release of acetylcholine by Die-Huang-Wan to enhance insulin secretion for lowering plasma glucose in Wistar rats. | 2002 Sep 30 |
|
| Resolving the composite trait of hypertension into its pharmacogenetic determinants by acute pharmacological modulation of blood pressure regulatory systems. | 2003 Jan |
|
| Central cardiovascular action of urotensin II in conscious rats. | 2003 Jan |
|
| The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure. | 2003 Nov 28 |
|
| Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats. | 2006 Aug 14 |
|
| Release of acetylcholine to raise insulin secretion in Wistar rats by oleanolic acid, one of the active principles contained in Cornus officinalis. | 2006 Aug 14 |
|
| Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats. | 2006 Dec |
|
| Effects of chronic treatment with 7-nitroindazole in hyperthyroid rats. | 2006 Nov |
|
| Vasorelaxant activity of some oxime derivatives. | 2007 Dec 1 |
|
| Total peripheral resistance responsiveness during the development of secondary renal hypertension in dogs. | 2007 Mar |
|
| The participation of brain NO synthase in blood pressure control of adult spontaneously hypertensive rats. | 2007 Mar |
|
| Cardiovascular effects of L-glutamate microinjection in the supraoptic nucleus of unanaesthetized rats. | 2007 May |
|
| Cardiovascular effects of noradrenaline microinjection in the bed nucleus of the stria terminalis of the rat brain. | 2007 May 15 |
|
| Angiotensin II-based hypertension and the sympathetic nervous system: the role of dose and increased dietary salt in rabbits. | 2007 Sep |
|
| Cardiovascular responses to noradrenaline microinjection in the ventrolateral periaqueductal gray of unanesthetized rats. | 2008 Feb 15 |
|
| Cardiovascular effects of noradrenaline microinjection into the medial part of the superior colliculus of unanesthetized rats. | 2009 Sep 22 |
|
| Role of sympathetic tone in BSO-induced hypertension in mice. | 2010 Aug |
Sample Use Guides
intramuscularly: 1 to 2 0.25-mg ampoules
Ansolysen must be used with caution. The initial dose is from 20-40 mg., taken 15 to 20 minutes before each meal and at bedtime, to ensure an even digestive absorption. Each dose is increased by 20-40 mg. four times a day at intervals of five to seven days until the desired hvpotensive effect is obtained. The maintenance dose varies generally between 160 and 800 mg. a day.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:12:11 UTC 2023
by
admin
on
Fri Dec 15 16:12:11 UTC 2023
|
| Record UNII |
ULL76WPU5X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66886
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2096
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
Pentolinium
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
347401
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
SUB03692MIG
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
DTXSID5048554
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
144-44-5
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
5850
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
C77367
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
100000085527
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
DB01090
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY | |||
|
ULL76WPU5X
Created by
admin on Fri Dec 15 16:12:11 UTC 2023 , Edited by admin on Fri Dec 15 16:12:11 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
